eISSN: 2081-2833
ISSN: 2081-0016
Medycyna Paliatywna/Palliative Medicine
Current issue Archive About the journal Abstracting and indexing Subscription Contact Instructions for authors
vol. 10
Review paper

Polish Association for Palliative Medicine stand on qualification for palliative care and management of patients with amyotrophic lateral sclerosis and multiple sclerosis

Anna Adamczyk, Magdalena Kwiatkowska, Iwona Filipczak-Bryniarska

MEDYCYNA PALIATYWNA 2018; 10(3): 115-130
Online publish date: 2018/11/22
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS). After craniocerebral injuries, it is the most common neurological disorder causing disability in young people.

In the advanced stage of MS, it is difficult to estimate life expectancy, but an important prognostic factor should be the rate of deterioration of a patient’s general condition. The burden of care in the advanced stage of the disease should be transferred from functional improvement of the patient to limitation of suffering and providing the patient with comfort.

Amyotrophic lateral sclerosis (ALS) is a degenerative disorder of the nervous system. Clinically, the disease is manifested by progressive limb paresis, dysarthric speech disorders, swallowing disorders and chronic progressive respiratory failure. ALS treatment is only symptomatic. An important element of care is to assist patients and their families in making decisions about further treatment and care and decisions about the end of life.

multiple sclerosis, amyotrophic lateral sclerosis, qualification for palliative care

Bartosik-Psujek H. Stwardnienie rozsiane. W: Neurologia. Stępień A (red.). Medical Tribune Polska 2015; 83-110.
Bradley WG, Daroff RB, Fenichel GB, Jankovic J. Neurologia w praktyce klinicznej. Czelej, Lublin 2006; 1931-1971.
Hauser SL. Harrison – Neurologia w medycynie klinicznej. Czelej, Lublin 2008; 479-500.
Mazur R. Neurologia kliniczna. Via Medica 2007; 271-283.
Samuels MA, Ropper AH. Leczenie w neurologii. Elsevier Urban & Partner, Wrocław 2014; 197-217.
Bartosik-Psujek H, Malec-Milewska M, Berkowicz T i wsp. Standardy postępowania w nowoczesnym leczeniu objawowym w stwardnieniu rozsianym. Zalecenia ekspertów. Medical Guidelines 2013; 1-19.
Sygut M. Jeden program lekowy ułatwiłby terapię pacjentów z SM. Rynek Zdrowia wrzesień – październik 2018; 51-57.
Losy J. Zmęczenie w stwardnieniu rozsianym. Farmakoter Psychiatr Neurol 2005; 3: 279-282.
Malec-Milewska M. Ból u chorych na stwardnienie rozsiane. Medycyna Paliatywna w Praktyce 2014; 8: 29-40.
Kmieć T. Spastyczność – leczenie farmakologiczne. Opieka Paliatywna nad Dziećmi 2008; 16: 135-139.
Ben-Zacharia AB, Lublin FD. Palliative care in patients with multiple sclerosis. Neurol Clin 2001; 19: 801-827.
Dzierżanowski T. Kanabinoidy – możliwości zastosowania w medycynie paliatywnej. Med Paliat 2018; 10: 1-11.
Brola W, Kasprzyk M, Fudala M, Opara J. Opieka paliatywna nad pacjentem ze stwardnieniem rozsianym. Med Paliat 2013; 5: 41-44.
Higginson IJ, Hart S, Silber E i wsp. Symptom prevalence and severity in people severely affected by multiple sclerosis. J Palliat Care 2006; 22: 158-165.
Bartosik-Psujek H, Malec-Milewska M, Berkowicz T i wsp. Nowoczesne leczenie objawowe w stwardnieniu rozsianym. Pol Przegl Neurol 2013; 9: 160-171.
Członkowska A, Członkowski A. Leczenie w neurologii – kompendium. Wydawnictwo Lekarskie PZWL 2004; 128-144.
Campbell CW, Jones EJ, Merrils J. Palliative and end-of-life care in advanced Parkinson’s disease and multiple sclerosis. Clin Med 2010; 10: 290-292.
Opara JA, Brola W, Szczygiel J. Palliative care in Polish patients with multiple sclerosis. J Palliat Care Med 2016; 6: 1-4.
Strupp J, Romotzky V, Galushko M i wsp. Palliative care for severely affected patients with multiple sclerosis: when and why? Results of a Delphi Survey of Health Care Professionals. J Palliat Med 2014; 17: 1128-1136.
Strupp J, Voltz R, Golla H. Opening locked doors: integrating a palliative care approach into the management of patients with severe multiple sclerosis. Mult Scler 2016; 22: 13-18.
De Walden-Gałuszko K, Ciałkowska-Rysz A. Medycyna paliatywna. Wydawnictwo Lekarskie PZWL, Warszawa 2015; 253-266.
Andersen PM, Abrahams S, Borasio GD i wsp. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) – revised report of an EFNS task force. Eur J Neurol 2012; 19: 360-375.
Hogden A, Foley G, Henderson RD i wsp. Amyotrophic lateral sclerosis: improving care with a multidisciplinary approach. J Multidiscip Healthc 2017; 10: 205-215.
Cedarbaum JM, Stambler N, Malta E i wsp. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci 1999; 169: 13-21.
Fang T, Al Khleifat A, Meurgey JH i wsp. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol 2018; 17: 416-422.
Bede P, Oliver D, Stodart J i wsp. Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives. J Neurol Neurosurg Psychiatry 2011; 82: 413-418.
Karam ChY, Paganoni S, Joyce N i wsp. Palliative care issues in amyotrophic lateral sclerosis: an evidenced-based review. Am J Hosp Palliat Care 2016; 33: 84-92.
Hobson EV, McDermott CJ. Supportive and symptomatic management of amyotrophic lateral sclerosis. Nat Rev Neurol 2016; 12: 526-538.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe